April 19, 2024

• 

[THE INVESTOR] Samsung BioLogics is unlikely to be delisted, and the fluctuating stock price is an opportunity to purchase its stocks, said Korea Investment and Securities on May 3. 

If it is confirmed to have violated accounting regulations, it could face delisting, but Korea Exchange takes into account continuity of the company, management transparency, public interest and investor protection. The odds of delisting are slim, said analyst Jin Hong-guk, citing Korea Aerospace Industries and Daewoo Shipping and Marine Engineering that too faced fraudulent accounting charges.

Moreover delisting the bio arm of Samsung will have a significant impact as it could lead to a discount of Korean bio and pharmaceutical industry as a whole. For now, the uncertainty may shake the stock price but when the risks are cleared it would be a chance to purchase them for a low price, he added.

By Hwang You-mee (glamazon@heraldcorp.com)